The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3

Journal of Immunotherapy

Volumn 27, Issue 6, 2004, Pages 419-424

  Smallshaw, Joan E ^a   Coleman, Elaine ^a   Spiridon, Camelia ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ADCC; Biodistribution; CD54; CDC; Chimeric antibody; ICAM I; Multiple myeloma; Pharmacokinetics; SCID mouse tumor model

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY UV3; IMMUNOGLOBULIN G1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY UV3; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BINDING AFFINITY; CHIMERA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INOCULATION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; SCID MOUSE; TREATMENT OUTCOME; TUMOR CELL;

EID: 7444229812     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200411000-00001     Document Type: Article

References (36)

1. Huang YW, Vitetta ES. Immunotherapy of multiple myeloma. Stem Cells. 1994;13:123-134.
2. Greenlee RT, Hill-Harmon MB, Murry T. Cancer statistics. CA Cancer J Clin. 2001;51:15-36.
3. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother. 2002;56:133-138.
4. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
5. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875-887.
6. Ribas C, Collioni GWB. Advances in the treatment of multiple myeloma: the role of thalidomide. Leuk Lymphoma. 2003;44:291-298.
7. Bensinger WI. Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomed Pharmacother. 2002;56:133-138.
8. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
9. Raje N, Anderson K. Thalidomide: a revival story. N Engl J Med. 1999;341:1606-1609.
10. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol. 2003;120:10-17.
11. Huang YW, Burrows FJ, Vitetta ES. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma. 1993;12:661-675.
12. Boyd AW, Wawryk SO, Bums GF, et al. Intercellular adhesion molecule-1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci USA. 1988;85:3095-3099.
13. Wawryk SO, Novotny JR, Wicks IP, et al. The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev. 1989;108:135-161.
14. Salomon B, Bluestone JA. LFA-1 interactions with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol. 1998;161:5138-5142.
15. Abraham C, Griffith J, Miller J. The dependence for leukocyte function-associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high-density TCR ligand. J Immunol. 1999;162:4399-4405.
16. Johnson JP, Stade BG, Holzmann B, et al. De novo expression of intercellular adhesion molecule in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA. 1989;86:641-644.
17. Stauder R, Greil R, Shulz TF, et al. Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1(ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour. Clin Exp Immunol. 1989;77:234-238.
18. Horst E, Radaszkiewicz T, Otter AH, et al. Expression of the leukocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia. 1991;5:848-853.
19. Ahsmann EJM, Lokhorst HM, Dekker AD, et al. Lymphocyte function-associated antigen-1 expression on plasma cells correlated with tumor growth in multiple myeloma. Blood. 1992;79:2068-2075.
20. Koga H, Naito S, Nakashima M, et al. A flow cytometric analysis of the expression of adhesion molecules on human renal cell carcinoma cells with different metastatic potentials. Eur Urol. 1997;31:86-91.
21. Shimoyama S, Gansauge F, Gansauge S, et al. Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas. Pancreas. 1997;14:181-186.
22. Jiang Z, Woda BA, Savas L, et al. Expression of ICAM-1, VCAM-1, and LFA-1 in adenocarcinoma of the lung with observations on the expression of these adhesion molecules in non-neoplastic lung tissue. Mod Pathol. 1998;11:1189-1192.
23. Huang YW, Richardson JA, Tong AW, et al. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res. 1993;53:1392-1396.
24. Huang YW, Richardson JA, Vitetta ES. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 1995;55:610-616.
25. Sambrook J, Maniatis T, Fritsch EF. Molecular Cloning: A Laboratory Manual, 2d ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989:1-545.
26. Coloma MJ, Hastings A, Wims LA, et al. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods. 1992;152:89-104.
27. Flieger D, Gruber R, Schlimok G, et al. A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods. 1995;180:1-13.
28. Fraker PJ, Speck JCJ. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
29. Shumaker RC. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17:331-348.
30. Ober RJ, Radu CG, Ghetie V, et al. Differences in promiscuity for antibody- FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13:1250-1255.
31. Ghetie V, Ward ES, Vitetta ES. Pharmacokinetics of antibodies and immunotoxins in mice and humans. In: Figg WD, McLeod HL, eds. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Totowa, NJ: Humana Press Inc, 2004:475-498.
32. Kavanaugh AF, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994;37:992-999.
33. Wacholtz MC, Patel SS, Lipsky PE. Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med. 1989;170:431-448.
34. Kavanaugh AF, Schulze-Koops H, Davis LS, et al. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 1997;40:849-953.
35. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62.
36. Vitetta ES, Coleman E, Ghetie M-A, et al. Immunotherapy. In: Paul W, ed. Fundamental Immunology, 5th ed. New York: Lippincott Williams & Wilkins, 2003:1621-1659.